Summary The NeoSep1 trial is expected to enroll 3,000 newborns across Asia and Africa by the end of 2028.
Along with India, newborns have already been enrolled in Ghana, Kenya, and South Africa.
Hospitals in Vietnam, Pakistan, Malaysia, Bangladesh, and Uganda are also expected to join the study.
Summary The NeoSep1 trial is expected to enroll 3,000 newborns across Asia and Africa by the end of 2028. Along with India, newborns have already been enrolled in Ghana, Kenya, and South Africa. Hospitals in Vietnam, Pakistan, Malaysia, Bangladesh, and Uganda are also expected to join the study.
